Pfizergan Would Have Challenged Novartis For 2015 Approvals Crown
Novartis had the most new molecular entity approvals in 2015 with four, all developed in house; next in line is Allergan, with three approvals that stem from acquisitions and licensing.
You may also be interested in...
No company received more than two approvals among the 28 novel agents approved in 2016 by US FDA's drug and biologics centers combined.
Acquisition is based on the prospects for Immunomedics’ Trodelvy, but regulatory changes, manufacturing challenges, and research dynamics could upset even the best-laid plans.
Keeping Track: Terlipressin Falls Short Of US FDA Approval; Novel NDAs From Pfizer And Apellis; New BTDs For Sanofi, BeyondSpring
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.